Equine performance genes and the future of doping in horseracing.
暂无分享,去创建一个
[1] F. Giordano,et al. Gene-based therapeutic angiogenesis. , 2003, Seminars in thoracic and cardiovascular surgery.
[2] H. Birch,et al. A review of tendon injury: why is the equine superficial digital flexor tendon most at risk? , 2010, Equine veterinary journal.
[3] A. Hahn,et al. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise , 2002, European Journal of Applied Physiology.
[4] J. Zierath,et al. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. , 2013, Cell metabolism.
[5] C. Bustamante,et al. A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs , 2007, PLoS genetics.
[6] P. Houweling,et al. Sequence analysis of the equine ACTN3 gene in Australian horse breeds. , 2014, Gene.
[7] M. Déry,et al. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. , 2005, The international journal of biochemistry & cell biology.
[8] S. Ohno,et al. Genetically directed preferential X-activation seen in mice , 1974 .
[9] M. Thevis,et al. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. , 2009, Journal of mass spectrometry : JMS.
[10] O. Distl,et al. Candidate genes for physical performance in the horse. , 2011, The Veterinary Journal.
[11] N. Kara,et al. PPAR-α and PPARGC1A gene variants have strong effects on aerobic performance of Turkish elite endurance athletes , 2014, Molecular Biology Reports.
[12] K. Ho,et al. Growth hormone and physical performance , 2011, Trends in Endocrinology & Metabolism.
[13] Eugene Muchnik,et al. HIF prolyl hydroxylase inhibitors for anemia , 2011, Expert opinion on investigational drugs.
[14] M. Thevis,et al. Identification of fibroblast growth factor 1 (FGF-1) in a black market product. , 2011, Drug testing and analysis.
[15] P. Teale,et al. Impact of the emergence of designer drugs upon sports doping testing , 2009 .
[16] B. Kieffer,et al. Opiates: basic mechanisms , 2006 .
[17] L. Chandler,et al. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] R. Shephard,et al. The Cytokine Response to Physical Activity and Training , 2001, Sports medicine.
[19] C. Lundby,et al. Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015 , 2014, British Journal of Sports Medicine.
[20] D. Popov,et al. PPARα gene variation and physical performance in Russian athletes , 2006, European Journal of Applied Physiology.
[21] E. Hill,et al. Characterization of the equine skeletal muscle transcriptome identifies novel functional responses to exercise training , 2010, BMC Genomics.
[22] E. Hill,et al. Targets of selection in the Thoroughbred genome contain exercise-relevant gene SNPs associated with elite racecourse performance. , 2010, Animal genetics.
[23] C. Kahn,et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. , 1998, Molecular cell.
[24] T. Wan,et al. Doping control analyses in horseracing: a clinician's guide. , 2014, The Veterinary Journal.
[25] B. Langley,et al. Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression* , 2002, The Journal of Biological Chemistry.
[26] Ramakant Gupta,et al. FIBROBLAST GROWTH FACTOR (FGF): A REVIEW , 2013 .
[27] I. Ahmetov,et al. Effect of HIF1A gene polymorphism on human muscle performance , 2008, Bulletin of Experimental Biology and Medicine.
[28] James M. Wilson,et al. Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. , 2015, Human gene therapy methods.
[29] D. MacArthur,et al. Genes and human elite athletic performance , 2005, Human Genetics.
[30] M. Haskins,et al. Large animal models and gene therapy , 2006, European Journal of Human Genetics.
[31] J. Bertram,et al. Insulin‐like growth factor‐I improves cellular and molecular aspects of healing in a collagenase‐induced model of flexor tendinitis , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[32] N. Orr,et al. A Sequence Polymorphism in MSTN Predicts Sprinting Ability and Racing Stamina in Thoroughbred Horses , 2010, PloS one.
[33] E. Barrey. Reviewe: Genetics and genomics in equine exercise physiology: an overview of the new applications of molecular biology as positive and negative markers of performance and health. , 2010, Equine veterinary journal. Supplement.
[34] E. Barton,et al. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. , 2006, Journal of applied physiology.
[35] E. G. Cothran,et al. Genetic Diversity in the Modern Horse Illustrated from Genome-Wide SNP Data , 2013, PloS one.
[36] L. Tentori,et al. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? , 2007, Pharmacological research.
[37] Zhen Yan,et al. Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. , 2011, Journal of applied physiology.
[38] Shahram Mohaghegh,et al. Doping and the Latest Prohibited List of the World Anti-Doping Agency (WADA) , 2013 .
[39] Anupama Koneru,et al. Endogenous Opioids: Their Physiological Role and Receptors , 2009 .
[40] J. Segura,et al. Recombinant Erythropoietin and Analogues: A Challenge for Doping Control , 2004, Therapeutic drug monitoring.
[41] J. Grieger,et al. scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy , 2015, Gene Therapy.
[42] R. Geor,et al. Insulin resistance in equids: possible role in laminitis. , 2006, The Journal of nutrition.
[43] S. Robertson,et al. Pain control in horses: what do we really know? , 2014, Equine veterinary journal.
[44] A. Musarò,et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] Paul D Robbins,et al. IL-1ra/IGF-1 Gene Therapy Modulates Repair of Microfractured Chondral Defects , 2007, Clinical orthopaedics and related research.
[46] D. Wells,et al. Gene doping: the hype and the reality , 2008, British journal of pharmacology.
[47] John Gleaves. Enhancing the Odds: Horse Racing, Gambling and the First Anti-Doping Movement in Sport, 1889–1911 , 2012 .
[48] M. Audran,et al. Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. , 2005, Journal of analytical toxicology.
[49] J. Adamson,et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.
[50] E. Hill,et al. Sequence variants at the myostatin gene locus influence the body composition of Thoroughbred horses. , 2011, The Journal of veterinary medical science.
[51] Nobuyuki Itoh,et al. Fibroblast growth factors , 2001, Genome Biology.
[52] J. Mendell,et al. Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates , 2009, Science Translational Medicine.
[53] Wilhelm Schänzer,et al. Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse-racing. , 2008, Rapid communications in mass spectrometry : RCM.
[54] J. Glorioso,et al. Gene therapy for the treatment of chronic peripheral nervous system pain , 2012, Neurobiology of Disease.
[55] E. Hill,et al. MSTN genotypes in Thoroughbred horses influence skeletal muscle gene expression and racetrack performance. , 2012, Animal genetics.
[56] B. Essén-Gustavsson,et al. Energy metabolism in relation to skeletal muscle fibre properties during treadmill exercise. , 1985, Equine veterinary journal.
[57] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[58] Yi Zhang,et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.
[59] Nicole SanGiacomo. The Impact of Myostatin Genetic Polymorphism on Muscle Conformation in the Horse , 2013 .
[60] J. Gibney,et al. The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport. , 2007, Endocrine reviews.
[61] Y. Meckel,et al. NRF2 intron 3 A/G polymorphism is associated with endurance athletes' status. , 2009, Journal of applied physiology.
[62] A. Abu-Seida. Regenerative Therapy for Equine Osteoarthritis: A Concise Review , 2015 .
[63] A. Thiruvenkadan,et al. Inheritance of racing performance of Thoroughbred horses , 2009 .
[64] D. Clemmons,et al. Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.
[65] C. Gabay,et al. Genetics: Mutations in the IL1RN locus lead to autoinflammation , 2009, Nature Reviews Rheumatology.
[66] V. Erspamer,et al. PHARMACOLOGICAL DATA ON DERMORPHINS, A NEW CLASS OF POTENT OPIOID PEPTIDES FROM AMPHIBIAN SKIN , 1981, British journal of pharmacology.
[67] Dirk Moser,et al. Establishment of two quantitative nested qPCR assays targeting the human EPO transgene , 2016, Gene Therapy.
[68] F. Sato,et al. Nucleotide sequence of equine erythropoietin and characterization of region-specific antibodies. , 2004, American journal of veterinary research.
[69] Scott M. Williams,et al. Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status , 2010, BMC Medical Genetics.
[70] R. Geor,et al. Chapter 1.1 – The horse as an athlete: a physiological overview , 2008 .
[71] A. Beineke,et al. Effect of a single injection of autologous conditioned serum (ACS) on tendon healing in equine naturally occurring tendinopathies , 2015, Stem Cell Research & Therapy.
[72] G. Gaffney,et al. Gene doping: a review of performance-enhancing genetics. , 2007, Pediatric clinics of North America.
[73] A. Nieß,et al. Direct and long-term detection of gene doping in conventional blood samples , 2011, Gene Therapy.
[74] K. Lindblad-Toh,et al. A Deletion in the Canine POMC Gene Is Associated with Weight and Appetite in Obesity-Prone Labrador Retriever Dogs , 2016, Cell metabolism.
[75] A. Baoutina,et al. Improved detection of transgene and nonviral vectors in blood. , 2013, Human gene therapy methods.
[76] C. McIlwraith,et al. Therapeutic use of stem cells in horses: which type, how, and when? , 2013, Veterinary journal.
[77] N. Orr,et al. Correction: A Sequence Polymorphism in MSTN Predicts Sprinting Ability and Racing Stamina in Thoroughbred Horses , 2010, PLoS ONE.
[78] A. Ducasse,et al. Genomic structure, polymorphism and expression of the horse alpha-actinin-3 gene. , 2012, Gene.
[79] F. Piras,et al. Genome-wide evolutionary and functional analysis of the Equine Repetitive Element 1: an insertion in the myostatin promoter affects gene expression , 2015, BMC Genetics.
[80] N. Robinson,et al. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. , 2012, Drug testing and analysis.
[81] Eric Meadows,et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[82] B. Hamilton,et al. Growth factor delivery methods in the management of sports injuries: the state of play , 2007, British Journal of Sports Medicine.
[83] Kwan Hee Lee,et al. Cell mediated gene therapy: A guide for doctors in the clinic , 2015 .
[84] Iain Watt,et al. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. , 2001, Seminars in arthritis and rheumatism.
[85] Mai M H Mansour,et al. Gene doping: of mice and men. , 2009, Clinical biochemistry.
[86] J. Mendell,et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors , 2008, Proceedings of the National Academy of Sciences.
[87] E. Howley,et al. Criteria for maximal oxygen uptake: review and commentary. , 1995, Medicine and science in sports and exercise.
[88] H-T Huang,et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats , 2002, Gene Therapy.
[89] H. Sweeney,et al. Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. , 2004, Journal of applied physiology.
[90] L. W. Greene,et al. Physiologic and skeletal response to exogenous equine somatotropin (eST) in two-year-old Quarter Horses in race training , 1998 .
[91] M. Giacca,et al. Transgene Detection by Digital Droplet PCR , 2014, PloS one.
[92] M. Weitzman,et al. Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.
[93] J. Vine,et al. The detection of a synthetic Interleukin-1 receptor antagonist peptide in a seized product from a racing stable. , 2016, Drug Testing and Analysis.
[94] T. Wallimann. Bioenergetics: Dissecting the role of creatine kinase , 1994, Current Biology.
[95] A. Solinger,et al. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. , 2005, Arthritis and rheumatism.
[96] R. Verlengia,et al. Myostatin: genetic variants, therapy and gene doping , 2012 .
[97] Maria M. Mihaylova,et al. AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.
[98] Momiao Xiong,et al. Investigation gene and microRNA expression in glioblastoma , 2009, 2009 International Joint Conference on Bioinformatics, Systems Biology and Intelligent Computing.
[99] Florian Caiment,et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep , 2006, Nature Genetics.
[100] I. Alexander,et al. Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy , 2016, Gene Therapy.
[101] B. Swanepoel,et al. Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. , 2001, Rapid communications in mass spectrometry : RCM.
[102] J. Bartlett,et al. Inflammation and Immune Response of Intra-Articular Serotype 2 Adeno-Associated Virus or Adenovirus Vectors in a Large Animal Model , 2012, Arthritis.
[103] T. Noakes. Tainted glory--doping and athletic performance. , 2004, The New England journal of medicine.
[104] K. Graham,et al. The Effects of Growth Hormone on Body Composition and Physical Performance in Recreational Athletes , 2010, Annals of Internal Medicine.
[105] M. Gerard,et al. Effects of somatotropin and training on indices of exercise capacity in Standardbreds. , 2010, Equine veterinary journal. Supplement.
[106] C. Kawcak,et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. , 2007, American journal of veterinary research.
[107] J. Wood,et al. Factors associated with failure of thoroughbred horses to train and race. , 2010, Equine veterinary journal.
[108] T. Braun,et al. Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.
[109] Hung-Chih Kuo,et al. Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines , 2015, Stem Cell Research & Therapy.
[110] G. Lippi,et al. Telmisartan as metabolic modulator: a new perspective in sports doping? , 2012, Journal of strength and conditioning research.
[111] E. P. Cunningham,et al. Estimation of genetic trend in racing performance of thoroughbred horses , 1988, Nature.
[112] I. Macdougall,et al. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. , 2009, Advances in chronic kidney disease.
[113] S. Nakae,et al. Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice , 2000, The Journal of experimental medicine.
[114] D. MacArthur,et al. ACTN3 genotype is associated with human elite athletic performance. , 2003, American journal of human genetics.
[115] Se-Jin Lee,et al. Suppression of body fat accumulation in myostatin-deficient mice. , 2002, The Journal of clinical investigation.
[116] F. Booth,et al. Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. , 1991, Physiological reviews.
[117] E. Hill,et al. Association of sequence variants in CKM (creatine kinase, muscle) and COX4I2 (cytochrome c oxidase, subunit 4, isoform 2) genes with racing performance in Thoroughbred horses. , 2010, Equine veterinary journal. Supplement.
[118] J. Isner,et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.
[119] D. MacArthur,et al. ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. , 2013, The Journal of clinical investigation.
[120] C F Kearns,et al. Overview of horse body composition and muscle architecture: implications for performance. , 2002, Veterinary journal.
[121] G. S. Bains,et al. Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin as a model system , 2010, Gene Therapy.
[122] Y. Meckel,et al. Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance? , 2010, Metabolism: clinical and experimental.
[123] R. Samulski,et al. Autoimmune anemia in macaques following erythropoietin gene therapy. , 2004, Blood.
[124] Jos W. M. van der Meer,et al. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.
[125] J. Rivero. A scientific background for skeletal muscle conditioning in equine practice. , 2007, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.
[126] M. Flück. Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli , 2006, Journal of Experimental Biology.
[127] E. P. Cunningham,et al. Genetics of performance traits. , 2000 .
[128] E. Park,et al. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin , 2010, Molecular and Cellular Endocrinology.
[129] L. J. McCutcheon,et al. Effects of dexamethasone on glucose dynamics and insulin sensitivity in healthy horses. , 2007, American journal of veterinary research.
[130] J. N. MacLeod,et al. Genome Sequence, Comparative Analysis, and Population Genetics of the Domestic Horse , 2009, Science.
[131] G. Ferraz,et al. Polymorphisms in MCT1, CD147, PDK4, and DMRT3 genes in Arabian and Quarter Horses , 2017 .
[132] H Fessi,et al. Gene therapy and DNA delivery systems. , 2014, International journal of pharmaceutics.
[133] K. McKeever,et al. Low dose exogenous erythropoietin elicits an ergogenic effect in standardbred horses. , 2006, Equine veterinary journal. Supplement.
[134] Mai M H Mansour,et al. Doping in the recombinant era: strategies and counterstrategies. , 2005, Clinical biochemistry.
[135] T. Collares,et al. The use of genes for performance enhancement: doping or therapy? , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[136] D. Glass. IGF-1 Regulation of Skeletal Muscle Hypertrophy and Atrophy , 2010 .
[137] S. Mosler,et al. Modulation of Follistatin and Myostatin Propeptide by Anabolic Steroids and Gender , 2013, International Journal of Sports Medicine.
[138] A. Schambach,et al. Gene therapy on the move , 2013, EMBO molecular medicine.
[139] L. Ellegård,et al. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. , 2005, The Journal of clinical endocrinology and metabolism.
[140] E. Hill,et al. Horses for courses: a DNA-based test for race distance aptitude in thoroughbred racehorses. , 2012, Recent patents on DNA & gene sequences.
[141] Benjamin Stich,et al. Genome-wide association mapping of iron homeostasis in the maize association population , 2015, BMC Genetics.
[142] J. Wilson,et al. Delivery and evaluation of recombinant adeno‐associated viral vectors in the equine distal extremity for the treatment of laminitis , 2017, Equine veterinary journal.
[143] D. McMiken. An energetic basis of equine performance. , 1983, Equine veterinary journal.
[144] F. Gage,et al. Retrovirus‐Mediated Expression of an Artificial β‐Endorphin Precursor in Primary Fibroblasts , 1995, Journal of neurochemistry.
[145] P. R. van Weeren,et al. Effects of platelet‐rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: A placebo‐controlled experimental study , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[146] C. Velloso. Regulation of muscle mass by growth hormone and IGF‐I , 2008, British journal of pharmacology.
[147] C. Bouchard,et al. Muscle genetic variants and relationship with performance and trainability. , 1989, Medicine and science in sports and exercise.
[148] James Goss,et al. Gene therapy for pain: Results of a phase I clinical trial , 2011, Annals of neurology.
[149] T. Witte,et al. Intralesional injection of insulin-like growth factor-I for treatment of superficial digital flexor tendonitis in Thoroughbred racehorses: 40 cases (2000-2004). , 2011, Journal of the American Veterinary Medical Association.
[150] Peter Olson,et al. Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .
[151] A. Russell,et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. , 2003, Diabetes.
[152] L. Manchon,et al. Blood cells RNA biomarkers as a first long-term detection strategy for EPO abuse in horseracing. , 2010, Drug testing and analysis.
[153] Stuart Egginton,et al. Invited review: activity-induced angiogenesis , 2009, Pflügers Archiv - European Journal of Physiology.
[154] F. Parsa,et al. Avoiding Opioids and Their Harmful Side Effects in the Postoperative Patient: Exogenous Opioids, Endogenous Endorphins, Wellness, Mood, and Their Relation to Postoperative Pain. , 2016, Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health.
[155] M. Anshel,et al. Effect of aerobic and strength training on pain tolerance, pain appraisal and mood of unfit males as a function of pain location. , 1994, Journal of sports sciences.
[156] E. Birks,et al. LC−MS/MS Method for Confirmation of Recombinant Human Erythropoietin and Darbepoetin α in Equine Plasma , 2007 .
[157] Martial Saugy,et al. The athlete biological passport. , 2011, Clinical chemistry.
[158] Robert A. Harris,et al. Role of Pyruvate Dehydrogenase Kinase 4 in Regulation of Blood Glucose Levels , 2010, Korean diabetes journal.
[159] M. Bidlingmaier,et al. Doping with Growth Hormone , 2001, Journal of pediatric endocrinology & metabolism : JPEM.
[160] C. McIlwraith,et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene , 2002, Gene Therapy.
[161] L. Regitano,et al. Comparison of Sequence Variants in the PDK4 and COX4I2 Genes Between Racing and Cutting Lines of Quarter Horses and Associations With the Speed Index , 2016 .
[162] L. Douglass,et al. expression and , 2006 .
[163] F. Bressolle,et al. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses. , 1996, Biopharmaceutics & drug disposition.
[164] Adam Bagg,et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.
[165] Kerry R Emslie,et al. Developing strategies for detection of gene doping , 2008, The journal of gene medicine.
[166] M. Rivera,et al. Role of Creatine Kinase Isoenzymes on Muscular and Cardiorespiratory Endurance , 2001, Sports medicine.
[167] H. Lee,et al. Molecular Characterization and Expression Analysis of the Peroxisome Proliferator Activated Receptor Delta (PPARδ) Gene before and after Exercise in Horse , 2015, Asian-Australasian journal of animal sciences.
[168] S. Welle,et al. Inventory of high-abundance mRNAs in skeletal muscle of normal men. , 1999, Genome research.
[169] E. Hill,et al. PGC-1α encoded by the PPARGC1A gene regulates oxidative energy metabolism in equine skeletal muscle during exercise. , 2012, Animal genetics.
[170] J. Tidball. Inflammatory processes in muscle injury and repair. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.
[171] A. Mobasheri,et al. Cobalt chloride doping in racehorses: Concerns over a potentially lethal practice. , 2015, Veterinary journal.
[172] K. Maiese,et al. Angiogenesis and plasticity: role of erythropoietin in vascular systems. , 2002, Journal of hematotherapy & stem cell research.
[173] Se-Jin Lee,et al. Double muscling in cattle due to mutations in the myostatin gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[174] E. Hill,et al. Alterations in oxidative gene expression in equine skeletal muscle following exercise and training. , 2010, Physiological genomics.
[175] A. Pokrywka,et al. GENES IN SPORT AND DOPING , 2013, Biology of sport.
[176] A. Jamurtas,et al. β-Endorphin Response to Exercise , 1997 .
[177] Se-Jin Lee,et al. Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[178] I. Alexander,et al. Potential use of gene transfer in athletic performance enhancement. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[179] B. Le Bizec,et al. Identification of recombinant equine growth hormone in horse plasma by LC-MS/MS: a confirmatory analysis in doping control. , 2008, Analytical chemistry.
[180] G. Semenza,et al. HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells , 2007, Cell.
[181] Theodore Friedmann,et al. Gene doping in sports: the science and ethics of genetically modified athletes. , 2011, Advances in genetics.
[182] Seungwoo Hwang,et al. Whole transcriptome analyses of six thoroughbred horses before and after exercise using RNA-Seq , 2012, BMC Genomics.
[183] T. Gustafsson. Vascular remodelling in human skeletal muscle. , 2011, Biochemical Society transactions.
[184] Peter H. Sönksen,et al. Insulin, growth hormone and sport. , 2001 .
[185] Z Domljan,et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.
[186] Y. Meckel,et al. Do PPARGC1A and PPARα polymorphisms influence sprint or endurance phenotypes? , 2010, Scandinavian journal of medicine & science in sports.
[187] J. Fisher,et al. Erythropoietin: Physiology and Pharmacology Update 2 , 2003, Experimental biology and medicine.
[188] M. Fedoruk,et al. Myostatin inhibition: a potential performance enhancement strategy? , 2008, Scandinavian journal of medicine & science in sports.
[189] E. Hill,et al. Moderate and high intensity sprint exercise induce differential responses in COX4I2 and PDK4 gene expression in Thoroughbred horse skeletal muscle. , 2010, Equine veterinary journal. Supplement.
[190] J. Davis,et al. Role of brain IL-1beta on fatigue after exercise-induced muscle damage. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[191] Henriette Pilegaard,et al. Exercise induces transient transcriptional activation of the PGC‐1α gene in human skeletal muscle , 2003, The Journal of physiology.
[192] T. Wirth,et al. History of gene therapy. , 2013, Gene.
[193] D. Bienzle,et al. Reticulocyte changes after experimental anemia and erythropoietin treatment of horses. , 2005, Journal of applied physiology.
[194] U. Ekelund,et al. PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. , 2005, Journal of applied physiology.
[195] M. Penaud-Budloo,et al. Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping , 2011, Gene Therapy.